Is it safe?
Can RYTM take a bad year?
Rhythm Pharmaceuticals, Inc. holds $225M more cash than debt, so a bad year is a question about profits, not about lenders.
$225M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 9.10
Altman Z-score · safe zone, above 3
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
Details›
- Total debtQ2 2026
- $106M
- Cash and short-term investments
- $331M
- Net cash
- $225M
- Operating profit, trailing twelve months
- −$201M
- Debt / equity
- 1.03×
- Annualised volatilitytwo years of daily moves
- 53%
- Worst drawdown on file
- −92%
- Below its 52-week high
- −4.9%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.